Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib Maintenance in AML Patients in Remission
NCT00093470Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2004
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Arm A (tipifarnib) with Arm B (clinical observation) (2 arms). Primary endpoint: Disease-free Survival up to 5 years. Started Aug 2004; status: completed.
02
Drugs
tipifarnib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00093470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093470.